By Connor Hart
Edesa Biotech named Peter Weiler as its finance chief, succeeding Stephen Lemieux, effective May 1.
Weiler, 56, has experience in finance and corporate strategy with both the biotechnology and pharmaceutical industries, the Toronto-based company said Friday.
He most recently was president of Exzell Pharma, a privately held, commercial-stage pharmaceutical company. Prior, he held executive posts at companies including Biosyent and Cipher Pharmaceuticals, as well as research and financial positions at Eli Lilly Canada.
Weiler will receive an annual base salary of $300,000. He will additionally be eligible for a target annual bonus valued at 40% of his base salary, as well as other benefits, according to a filing with the Securities and Exchange Commission.
Weiler succeeds Lemieux, who is stepping down as CFO to pursue other professional opportunities. He will continue to provide financial advisory services to Edesa on a contract basis following the planned transition, the company said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 04, 2025 16:41 ET (20:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。